# Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes

> **NCT05610332** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fujian Medical University** · enrollment: 216 (estimated)

## Conditions studied

- Locally Advanced Gastric Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Albumin Taxol
- **DRUG:** FLOT scheme

## Key facts

- **NCT ID:** NCT05610332
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2024-11-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 216 (ESTIMATED)
- **Last updated:** 2022-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05610332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05610332, "Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05610332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*